top of page

A deep dive into antibody-drug conjugates with Daiichi Sankyo's Ken Keller

Ken Keller describes recent advances in ADC technology, talks about the recent Merck deal, and what it was like to change breast cancer at ASCO in 2022.




Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page